| Term 
 | Definition 
 
        | Protein therapeutics with enzymatic or regulatory activity |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Replace a protein which is deficient or abnormal 
 
 •	Factor VIII
 •	Insulin and its analogues
 •	Growth Hormone
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Augment an existing pathway 
 
 •	Erythropoietin
 •	Pegylated interferon
 •	Tenecteplase
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Provide a novel function or activity 
 
 •	Collagenase
 •	L-asparaginase
 •	Etanercept
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Protein therapeutics with special targeting activity |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Interfering with a molecule or organism by binding to it and blocking its function or targeting it for degradation 
 •	Abciximab
 
 •	Enfuviritide
 •	Infliximab
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Stimulating a signalling pathway 
 •	Trastuzumab
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Delivering other compounds or proteins 
 •	Gemtuzumab ozagamicin
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Protecting against a deleterious foreign agent 
 
 •	HBsAg
 •	Lyme disease (Borrelia burgdorfei)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Treating an autoimmune disease 
 •	Anti-Rh IgG
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Treating cancer 
 •	Currently in clinical trials
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Protein diagnostic 
 
 	HIV antigens
 	Hepatitis C antigens
 	Thyroid stimulating hormone (TSH)
 	Glucagon
 |  | 
        |  | 
        
        | Term 
 
        | Sympathetic preganglionic neurons |  | Definition 
 
        | arise in the ventral horn of the thoracic and lumbar segments of the spinal cord and project onto postganglionic neurons in the paravertebral and prevertebral ganglia. 	Sympathetic postganglionic neurons innervate many organs, including smooth muscle.
 •	The adrenal medulla is innervated by preganglionic neurons of the sympathetic nervous system
 |  | 
        |  | 
        
        | Term 
 
        | Parasympathetic preganglionic neurons |  | Definition 
 
        | arise in nuclei in the brainstem/sacral segments of the spinal cord and project onto postganglionic neurons in ganglia located near the innervated organs. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 	Pharmacological M-agonist bethanecol (GI and urinary tract motility) 	M-antagonist atropine (dilate pupils/ increase heart rate) action
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 	Albuterol (B2 agonist) dilate bronchioles selectively vs. 	Metroprolol (B2 antagonist) selectively decrease heart rate
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | (agonist of NMJ) increase skeletal muscle stimulation (Myasthenia gravis treatment) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | (antagonist of NMJ) induces paralysis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 	parasympathetic and somatic neuromuscular junctions. 	Few sympathetic neuroeffector junctions; sweat glands and vasodilator fibers in skeletal muscle.
 	lack of specificity of drugs acting on acetylcholine neurotransmission
 |  | 
        |  | 
        
        | Term 
 
        | o	Norepinephrine/ Ephinephrine |  | Definition 
 
        | 	Norepinephrine (noradrenaline) - Primary neurotransmitter at most sympathetic postganglionic neuroeffector junctions, 	Epinephrine (adrenaline) is the principal catecholamine released from the adrenal medulla
 |  | 
        |  | 
        
        | Term 
 
        | o	Other neurotransmitters |  | Definition 
 
        | 	autonomic nerves of the GI tract, genitourinary tract and certain blood vessels. 	neuropeptide Y, vasoactive intestinal polypeptide, enkephalin, substance P, serotonin, adenosine triphosphate, and nitric oxide.
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | o	Parasympathetic neuroeffector junctions o	M1-M5 human GPCR – G-Protein Coupled Receptor
 	M3 receptor- smooth muscle contraction and gland secretion.
 	M2 receptor- mediates cardiac slowing
 	M1 receptor -modulation of neurotransmission at central and peripheral sites.
 o	Activation in skeletal muscle causes muscle contraction.
 o	M1, M3 and M5 stimulation of PLC, IP3 and DAG
 o	M2 and M4 inhibition AC and K+ channel activation
 o	Hyperpolarization of the cell
 o	Latency 100-250 ms
 |  | 
        |  | 
        
        | Term 
 
        | Nicotinic receptor action |  | Definition 
 
        | o	Found in all autonomic ganglia (Nn neuron Nm muscle) o	NN  –Neuronal- excites neurotransmission
 o	NM –somatic neuromuscular – excites muscle contraction
 o	NM:5 subunits; 30-50% homology
 o	NN:  and  subunits
 |  | 
        |  | 
        
        | Term 
 
        | Nicotinic receptor structure biology |  | Definition 
 
        | o	2 subunit - hydrophobic pocket serves as binding site for Ach agonist o	Predominant ion in nAChR is Na+,
 o	Net inward Na+ current depolarize the cell
 o	 Brief latency <10ms
 |  | 
        |  | 
        
        | Term 
 
        | Synthesis of Achetylcholine |  | Definition 
 
        | o	Choline sources: 	Synaptic Cleft
 	Plasma based  (lipid phosphatidylcholine)1
 	Phospholipids  (phosphorylcholine)
 o	Acetyl-CoA:
 	Glycolysis  (mitochondria)2
 o	Rate limiting steps of ACh: Choline uptake
 	Low affinity facilitated diffusion (Km=10-100M)
 	High affinity transport (Km=1-5M) 3
 |  | 
        |  | 
        
        | Term 
 
        | Cholinergic Neurotransmission |  | Definition 
 
        | o	direct-acting acetylcholine receptor agonists : bethanechol and pilocarpine, o	indirect-acting acetylcholine receptor agonists: cholinesterase inhibitors  (physostigmine), increase the synaptic concentration of Ach.
 o	acetylcholine receptor antagonists:
 o	 muscarinic receptor antagonists  (atropine)
 o	 nicotinic receptor antagonists /ganglionic blocking agents (e.g., trimethaphan) and neuromuscular blocking drugs (e.g., tubocurarine).
 |  | 
        |  | 
        
        | Term 
 
        | Effects of Acetylcholine on M receptors |  | Definition 
 
        | o	Eye iris 	contraction and miosis
 o	Salivary and lacrimal glad
 	thin and watery secretions
 o	Heart
 	Bradycardia
 	Lower conduction velocity
 	AV block in high doses
 	Slight lower in contractility
 |  | 
        |  | 
        
        | Term 
 
        | How does botulinum toxine cause muscle weakness and prolonged paralysis? |  | Definition 
 
        | o	Degrades synaptobrevin and prevents the fusion of presynaptic storage vesicles with the cell membrane |  | 
        |  | 
        
        | Term 
 
        | •	A woman with facial muscle spasms is treated with an agent that inhibits the release of acetylcholine. Which side effect is most likely to occur in this patient? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | 	Norepinephrine (NE), the principal transmitter of most sympathetic postganglionic fibers 	dopamine (DA), the predominant transmitter of the extrapyramidal system, mesocortical and mesolimbic neuronal pathways
 	epinephrine, the major hormone of the adrenal medulla
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | •	mediate smooth muscle and glands contraction |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | •	cause transmitter release, contraction |  | 
        |  | 
        
        | Term 
 
        | Activation of β1-adrenoceptors |  | Definition 
 
        | •	produces cardiac stimulation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | •	mediate smooth muscle relaxation |  | 
        |  | 
        
        | Term 
 
        | Adrenergic Neurotransmition |  | Definition 
 
        | 	Direct- acting adrenoceptor agonists - albuterol, epinephrine 	Indirect- acting adrenoceptor agonists
 •	 Amphetamine(+), cocaine(-)
 o	Acts on reuptake of NE
 •	 COMT or MAO inhibitors (primarily effects on CNS )
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | selectively blocks α-adrenoceptors |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | selective β-adrenoceptors blocker |  | 
        |  | 
        
        | Term 
 
        | 	Inhibit synthesis of neurotransmitter |  | Definition 
 
        | •	Hemicholinium •	Metyrosine (alpha-methyl-para-tyrosine)
 |  | 
        |  | 
        
        | Term 
 
        | 	Prevent vesicular storage of neurotransmitter |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | 	Inhibit release of neurotransmitter |  | Definition 
 
        | •	Botulinum toxin •	Bretylium
 |  | 
        |  | 
        
        | Term 
 
        | 	Increase release of neurotransmitter |  | Definition 
 
        | •	Black widow spider venom (α-latrotoxin)* •	Amphetamine
 |  | 
        |  | 
        
        | Term 
 
        | 	Inhibit reuptake of neurotransmitter |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | 	Inhibit metabolism of neurotransmitter |  | Definition 
 
        | •	Cholinesterase inhibitors (physostigmine) •	Monoamine oxidase inhibitors (phenelzine)
 |  | 
        |  | 
        
        | Term 
 
        | 	Activate postsynaptic receptors |  | Definition 
 
        | •	Acetylcholine, bethanechol, and pilocarpine •	Albuterol, dobutamine, and epinephrine
 |  | 
        |  | 
        
        | Term 
 
        | 	Block postsynaptic receptors |  | Definition 
 
        | •	Atropine and tubocurarine (block muscarinic and nicotinic receptors, respectively) •	Phentolamine and propranolol (block α- and β-adrenoceptors, respectively)
 |  | 
        |  | 
        
        | Term 
 
        | o	Epinephrine/Norepinephrine …? |  | Definition 
 
        | 	Are released by adrenal medulla pon binding to  2 adrenoceptors Ep cause smooth muscle relaxation
 |  | 
        |  | 
        
        | Term 
 
        | o	In a sympathetic postganglionic nerve ending which of the following blocks the conversion of an intermediate amino acid? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | 	Cortex- site of action of many drugs 	Basal ganglia -  intended actions , movement (PD)
 	Limbic system: cingulate gyrus, Hippocampus, amygdala- emotions, social behaviour (AD)
 |  | 
        |  | 
        
        | Term 
 
        | o	Pharmcological modification of Brain regions |  | Definition 
 
        | 	 Barbiturates and Benzodiazepines hypnotic/sedetative agents potentiate the action of inhibitory neurotransmitters in cortex. 	Levodopa acts on the dopaminergic neurotransmission and ameliorates symptoms of Parkinson disease in striatum
 	 Drugs that affect limbic system (hippocampus) and cholinergic neurotransmittion are used in Alzheimers Disease
 |  | 
        |  | 
        
        | Term 
 
        | o	Neurotrasmitters in CNS |  | Definition 
 
        | 	Exitatory (E, D) 	Inhibitary (G, GABA)
 	Glutamate act on both ionotropic and metabotropic receptors
 •	Overactivation of glutamate receptors lead to ischemic brain injury (neuronal death)
 •	Felbamate
 o	used in treatment of refractory epilepsy
 o	inhibits NMDA receptors -> reduce excessive neuronal activity
 	GABA acts on GABA receptors
 •	Barbiturates and benzodiazepines and potentiate the effect of endogenous GABA
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | •	Subtantia niagra-control intended actions/ movements (PD –SN degeneration) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | •	Locus ceruleus- maintain vigilance, responsiveness to unexpected stimulus •	COCAIN- activate this system by inhibiting reuptake of norepinephrine – Hypervigilance
 •	TCA (antidepressant) blocks reuptake of NE
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | •	Brain stem (raphe nuclei) – modulating pain, regulate wakeness/ sleep •	Depression- dysfunction of seretonin system
 •	(SSRIs- used for treatment of depression)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | •	Nucleus : Alertness/ sleep-awake cykle, AD |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | •	Hypothalamus:  forbrain arousal. Antihistamines •	(H1 receptor antagonist) used to treat allergies.
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 	Peripheral mechanism of action: 	Its released from nerves (nitrergic) innervating blood vessels and smooth muscles of the GI
 	Endothelial cell–dependent mechanisms of relaxation including the coronary circulation.
 	Activates specific GPCRs ->promotes NO production.
 	activating  GC->  cyclic GMP
 	Nitrovasodilating act through conversion to or release of NO
 	CNS mechanism of action:. NO is a small protein neurotransmitter
 •	Binds to receptors residing in the presynaptic neuron.
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 	Endocrine, aoutocrine and paracrine effects 	Opioids, Tachykinins, Secretins, Insulines
 	Piturary hormone release : CRH, GnRH, TRH, GRH
 	Opioid receptors in the spinal cord and brain mostly involved in pain sensation: Pharmacological targets of analgesics (morphine) and drug abuse (heroin)
 |  | 
        |  | 
        
        | Term 
 
        | o	Blood Brain Barrier (BBB) permeability |  | Definition 
 
        | 	Lipophilic substances, incl lipid soluble gases •	high w/o coefficient pass BBB
 	Hydrophilic substances (glucose) pass BBB only with help of specific transporters
 	Hexose transportes glucose
 	3 transporters involved in the transport of amino acids (L-DOPA but not dopamine)
 	Protection against toxic substances
 •	Multiple drug resistance transporters
 •	Metabolic BBB
 |  | 
        |  |